Старение. Профессиональный врачебный подход

   38. Caughey G.E., Vitry A.I., Gilbert A.L., Roughead E.E. Prevalence of comorbidity of chronic diseases in Australia // BMC Public Health, 2008; 8:221

   39. Chaitman B.R., Pepine C.J., Parker J.O. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial // JAMA. 2004. Vol. 291. № 3. P. 309–316.

   40. Chaitman B.R., Skettino S.L., Parker J.O. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina // J. Amer. Coll. Cardiology. 2004. Vol. 43. № 8. P. 1375–1382.

   41. Chang К. Т., Min K.-T. Regulation of lifespan by histone deacetylase // Ageing Res. Rev. 2002. Vol. 1. P. 313–326.

   42. Charlson M.E., Pompei P., Ales H.L. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation // Journal Chronic Disease, 1987; 40:373–383

   43. Ciunmings D.E., Merriam С.R. Growth hormone therapy in adults // Annu. Rev. Mcd. 2003. Vol. 54. P. 513–533.

   44. Clark W.R. Reflections on an unsolved problem of biology: the evolution of senescence and death. Advances in Gerontology. 2004. Vol. 14. P. 7–20.

   45. Cloninger C.R. Implications of comorbidity for the classification of mental disorders: the need for a psychobiology of coherence // Psychiatric Diagnosis and Classification, 2002; p. 79–105

   46. Cohen-Mansfield J, Kivity Y. The relationships among health behaviors in older persons.

   47. Cuijpers P., van Lammeren P., Duzijn B. Relation between quality of life and chronic illnesses in elderly living in residential homes: a prospective study // Int Psychogeriatr, 1999; 11: 445–454

   48. Cullen W., O’Brien S., O’Carroll A., O’Kelly F.D., Bury G. Chronic illness and multimorbidity among problem drug users: a comparative cross sectional pilot study in primary care. BMC Fam Pract. 2009 Apr 21;10:25.

   49. Dasgupta S. A computer simulation for biological aging J. de physique. 1994. Vol. 4. P. 1563–1570.

   50. Daveluy C., Pica L., Audet N. Enquête Sociale et de Santé 1998. 2nd ed. Québec: Institut de la statistique du Québec ; 2001

   51. DCCT Research Group Reliability and validity of a diabetes quality of life measure for the diabetes control and complications trial (DCCT) // Diabetes Care, 1998; 11:725–732

   52. De Boer J., van der Horsi G., Т., Hoeijmakers J.H. Mutant mice as a model of human diseases of aging. Defective transcription and premature aging // Tijdscr Gerontol. Ceriatr. 1999. Vol. 30. P. 168–170.

   53. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods.J Clin Epidemiol. 2003 Mar;56(3):221-9.

   54. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods // J. Clin Epidemiol, 2003; Mar;56(3):221-9

   55. Dean W., Biological Aging Measurement // Clinical Applications, 1986.397 р.

   56. Dean W. Biological aging measurement J. Gerontogeriatric s. 1998. Vol. 1. P. 4–5.

   57. Desai M.M., Bogardus S.T. Jr., Williams C.S., Vitagliano G., Inouye S.K. Development and validation of a risk-adjustment index for older patients: the high-risk diagnoses for the elderly scale // J Am Geriatr Soc. 2002; Mar; 50(3): 474-81

   58. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases // J Clin Epidemiol, 1992; Jun;45(6):613-9

   59. Diederichs C., Bartels D.B., Berger K. The Importance Of A Standardized Instrument To Assess The Burden Of Multimorbidity.J Gerontol A Biol Sci Med Sci. 2011 Sep 7

   60. Dozmorov I., Bartke A., Miller R. A. Array-based expression analysis of mouse liver genes: effect of age and of the longevity mutant Propldf J. Gerontol. A Biol. Sci. Med. Sci. 2001. Vol. 56. P. B72–B80.

   61. Dzerve V., Matisone D., Pozdnyakov Y., Oganov R. Mildronate improves the ex ercise tolerance in patients with stable angina: results of a long term clinical trial // Sem Cardiovasc Med. 2010; 16 (3): 1–8.

   62. Dzerve Vilnis, MILSS I Study Group. A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial «MILSS I» // Medicina (Kaunas) 2011; 47 (10): 544–551.

   63. Edgar D., Shabalina I., Camara Y., Wredenberg A., Calvaruso M.A., Nijtmans L., Nedergaard J., Cannon B., Larsson N.G., Trifunovic A. Random point mutations with major effects on protein-coding genes are the driving force behind premature aging in mtDNA mutator mice // Cell Metab. 2009 Aug;10(2):131-8.

   64. Elshtein N. Polymorbidity in gastroenterological practice. Acta Medico Baltica 1996; 1: 70-3.

   65. Evan G., Uttlewood T. A matter of life and cell death//Science. 1998. Vol.281. P. 1317–1322.

   66. Feinstein A.R. Pre-therapeutic class ification of co-morbidity in chronic disease // Journal Chronic Disease, 1970; 23(7):455–468